Date | Title | Description | |
---|---|---|---|
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 March and 7 March 2024 | Download |
07 Mar 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
01 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 23 February and 29 February 2024 | Download |
27 Feb 2024 | Annual Financial Reports and Audit Reports | The Company submits the 2023 Annual Financial Report | Download |
27 Feb 2024 | Annual Corporate Governance Report | ROVI releases the 2023 Annual Corporate Governance Report | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |